BioVision Lilly Award in Conjuction with TWAS

BioVision and the Lilly MDRTB Partnership create an award for young scientists, in conjunction with TWAS, the academy of sciences for the developing world

The BioVision Lilly Award, in conjunction with TWAS, the academy of sciences for the developing world, will honour outstanding scientific achievements made by individual young scientists from developing countries.

The prize will reward three young scientists living and working in a developing country, who have a track record of excellent research in infectious diseases, with an emphasis on tuberculosis preferred, and promise to have a positive impact in the developing world.

Candidates should be nationals of a developing country, under 40 years of age and hold at least a PhD degree with an outstanding academic background.

Three winners will be selected and invited to attend BioVision 2011 in Lyon, France from March 27‐29.

The winner and the first runner up will each receive funding to be used for his or her research.

The awards will be presented at a ceremony hosted by BioVision, TWAS and Lilly, during BioVision 2011.

Additional information and nomination forms are available from the TWAS Secretariat : or on the TWAS website.

About BioVision, the Lilly MDRTB Partnership and TWAS

TWAS, the academy of sciences for the developing world is an autonomous international organization founded in Trieste, Italy in 1983. TWAS represents the best of science in the developing world. Its principal aim is to promote scientific capacity and excellence for sustainable development in the South. The administration and financial operation of TWAS is undertaken by UNESCO in accordance with an agreement signed by the two organizations.

BioVision 2011 will take place on March 27‐29 in Lyon, France. BioVision engages key international leaders from different backgrounds in debates on global issues involving science and society. Every other year in Lyon, BioVision brings together government and business leaders, scholars, policy makers and NGO directors. Participants analyze scientific breakthroughs, pressing global challenges, discuss the most effective solutions, and build lasting partnerships that enable them to create positive social change.

The Lilly MDR‐TB Partnership

Recognizing that MDR‐TB cannot be halted by medicine alone, Lilly created the Lilly MDR‐TB Partnership in 2003. This public‐private initiative mobilizes over 20 partners on five continents to tackle the scourge of TB and MDR‐TB. Eli Lilly and Company is contributing US$ 120 million in cash, medicines, advocacy tools and technology to focus global resources on prevention, diagnosis and treatment of TB and MDRTB. An additional US$ 15 million was given to the Lilly TB Drug Discovery Initiative; a nonprofit with the goal of accelerating the discovery of new drugs to treat TB by bringing together specialists from around the world. The company has made this investment to ensure that thousands of MDR‐TB patients receive the care and medication they need to combat this disease.


Press contact:


Aurélie Bellemin

Alize PR :

Caroline Carmagnol

More News
30 Mar 2021
Médecins Sans Frontières (MSF) published a press release on World TB Day 2021 announcing their clinical trial, TB-Practecal , investigating novel treatment for MDR-TB has stopped enrolling earlier than originally planned due to promising results. The trial's independent data safety and monitoring...
3 Feb 2021
Last week, the World Health Organization (WHO) held a consultation to discuss the definition of extensively drug resistant (XDR) tuberculosis. The meeting was held to discuss novel treatment regimens and diagnostics for drug-resistant TB and determine its impact on the definition of XDR-TB. The...
10 Dec 2020
The Stop TB Partnership Working Group on New TB Vaccines (WGNV), Working Group on New TB Drugs (WGND), and New Diagnostics Working Group (NDWG) are developing an online course specifically designed for advocates and affected communities to provide a base of knowledge in TB research and to generate...